tbuckley/cabot-search huggingface dataset:
POS0026 LOSS OF PRODUCTIVITY IN MILD, MODERATE, AND SEVERE FIBROMYALGIA FEMALE WORKERS: CROSS-SECTIONAL STUDY
Authors: F. Salaffi, M. Di Carlo, S. Farah, C. Mariani, S. Fulginei, G. P. Martino, P. Sarzi-Puttini
Journal: Annals of the Rheumatic Diseases (2022)

Background Patients suffering from FM are challenged by symptoms such as chronic pain, fatigue, sleep disturbance and emotional distress. These symptoms lead to a physical capacity impairment, and FM patients report consequences on their activities of daily life and difficulties in fulfilling their work roles, resulting in reduced work capacity, presenteeism (coming to work despite health or personal issues, often resulting in a loss of productivity), absenteeism, and inability to work. Changes in ability to work are crucial to comprehend since they provide a more objective sign of function than other self-reported measures. Objectives To assess (a) the impacts of fibromyalgia (FM) symptoms on patients’ ability to work and (b) the relationship between FM severity level and lost productivity from the perspective of patients. Methods FM female patients were retrospectively evaluated for this cross-sectional study. FM severity was determined using the revised Fibromyalgia Impact Questionnaire (FIQR). Work Productivity and Activity Impairment-Fibromyalgia (WPAI-FM) was used to evaluate patients’ employment status. Differences across FM severity states were evaluated using the one-way analysis of variance (ANOVA) and chi-square or Fisher’s exact test. The Pearson’s r test was performed for the correlation analysis. Results The study included 209 subjects, 64 (30.6%) had mild, 64 (30.6%) had moderate, and 81 (38.8%) had severe FM; 57.9% were working full-time, and 42.1% were working part-time. According to WPAI-FM the work productivity and activity impairment resulted: absenteeism 7.03%; presenteeism 44.35%; activity impairment 47.24%; overall work productivity loss 58.23%. Disease severity was associated with decreased work productivity. Presenteeism, overall work productivity loss, and activity impairment demonstrated significant correlations with FIQR and PainDETECT Questionnaire. Conclusion FM severity is associated to a reduced job productivity. Early identification and treatment of FM may provide a window of opportunity for job preservation. References [1]Salaffi F, Mozzani F, Draghessi A et al (2016) Identifying the symptom and functional domains in patients with fibromyalgia: results of a cross-sectional Internet-based survey in Italy. J Pain Res 9:279-86. [2]Al-Allaf AW (2007) Work disability and health system utilization in patients with fibromyalgia syndrome. J Clin Rheumatol 13:199-201. [3]Mukhida K, Carroll W, Arseneault R (2020) Does work have to be so painful? A review of the literature examining the effects of fibromyalgia on the working experience from the patient perspective. Can J Pain 4:268-86. Figure 1. WPAI-FM scores ( A , absenteeism; B , presenteeism; C , activity impairment; D , work productivity loss) across FM severity states. Disclosure of Interests None declared
OP0120-HPR IMPACT OF DIFFERENT TYPES OF PHYSICAL ACTIVITY PROGRAMS ON ANKYLOSING SPONDYLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: J. Sigaux, R. Boudjani, S. Challal, L. Semerano
Journal: Annals of the Rheumatic Diseases (2022)

Background Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease characterized by inflammation and ankylosis of the spine. Spinal ankylosis is responsible for significant morbidity and disability. Despite public health campaigns supporting the benefits of physical activity (PA) the average level of PA in patients with AS is low. Objectives This systematic review and meta-analysis of controlled studies aimed to assess the efficacy of different types of physical activity (PA) programs on ankylosing spondylitis (AS) activity, function and mobility. Methods We searched PubMed/Medline, Cochrane Library and Embase databases for reports of controlled trials of patients with AS with at least one activity or function outcome published up to August 2020. The studies were classified by intervention into categories defined by the 4 dimensions of PA established by the World Health Organization: aerobic, muscle strength, flexibility and neuromotor performance. We performed both overall (including any kind of PA) and sub-group analysis by type of PA program. Results Forty-three studies were included in qualitative synthesis and 27 in meta-analysis. The overall analysis showed a moderate effect of PA on BASDAI (-0.57, 95% CI -0.92,-0.21, p=0.002), BASFI (-0.63, 95% CI -0.85,-0.42, p&lt;0.0001) and BASMI (-0.58, 95% CI -1.02,-0.14, p=0.01). The effect of “flexibility+muscle strength exercises” PA was large for BASMI (-1.03, 95% CI -1.64,-0.42, p=0.0009), moderate for BASDAI (-0.56, 95% CI -1.07,-0.05, p=0.03) and BASFI (-0.63, 95% CI -0.88,-0.39, p&lt;0.005). Home-based unsupervised “flexibility+muscle strength exercises” programs improved the BASFI but not BASDAI. The effect of “flexibility+muscle strength+aerobic exercises” PA was large for BASFI (-1.26, 95% CI -1.70,-0.81, p&lt;0.005), moderate for BASDAI (-0.77, 95% CI -1.40,-0.14, p=0.02). Conclusion PA has a moderate effect on AS activity and function. Programs including flexibility and muscle strength exercises may have a large effect, especially for spinal mobility. Programs including aerobic exercise showed significant efficacy for function. Disclosure of Interests None declared
Self-carried nanodrug (SCND-SIS3): A targeted therapy for lung cancer with superior biocompatibility and immune boosting effects
Authors: Guang-Yu Lian, Yingpeng Wan, Thomas Shiu-Kwong Mak, Qing-Ming Wang, Jinfeng Zhang, Jiaoyi Chen, Zi-Ying Wang, Min Li, Patrick Ming-Kuen Tang, Xiao-Ru Huang, Chun-Sing Lee, Xue-Qing Yu, Hui-Yao Lan
Journal: Biomaterials (2022)
Molecular profiling of human non-small cell lung cancer by single-cell RNA-seq
Authors: Qingqing Li, Rui Wang, Zhenlin Yang, Wen Li, Jingwei Yang, Zhijie Wang, Hua Bai, Yueli Cui, Yanhua Tian, Zixin Wu, Yuqing Guo, Jiachen Xu, Lu Wen, Jie He, Fuchou Tang, Jie Wang
Journal: Genome Medicine (2022)

Lung cancer, one of the most common malignant tumors, exhibits high inter- and intra-tumor heterogeneity which contributes significantly to treatment resistance and failure. Single-cell RNA sequencing (scRNA-seq) has been widely used to dissect the cellular composition and characterize the molecular properties of cancer cells and their tumor microenvironment in lung cancer. However, the transcriptomic heterogeneity among various cancer cells in non-small cell lung cancer (NSCLC) warrants further illustration.To comprehensively analyze the molecular heterogeneity of NSCLC, we performed high-precision single-cell RNA-seq analyses on 7364 individual cells from tumor tissues and matched normal tissues from 19 primary lung cancer patients and 1 pulmonary chondroid hamartoma patient.In 6 of 16 patients sequenced, we identified a significant proportion of cancer cells simultaneously expressing classical marker genes for two or even three histologic subtypes of NSCLC-adenocarcinoma (ADC), squamous cell carcinoma (SCC), and neuroendocrine tumor (NET) in the same individual cell, which we defined as mixed-lineage tumor cells; this was verified by both co-immunostaining and RNA in situ hybridization. These data suggest that mixed-lineage tumor cells are highly plastic with mixed features of different types of NSCLC. Both copy number variation (CNV) patterns and mitochondrial mutations clearly showed that the mixed-lineage and single-lineage tumor cells from the same patient had common tumor ancestors rather than different origins. Moreover, we revealed that patients with high mixed-lineage features of different cancer subtypes had worse survival than patients with low mixed-lineage features, indicating that mixed-lineage tumor features were associated with poorer prognosis. In addition, gene signatures specific to mixed-lineage tumor cells were identified, including AKR1B1. Gene knockdown and small molecule inhibition of AKR1B1 can significantly decrease cell proliferation and promote cell apoptosis, suggesting that AKR1B1 plays an important role in tumorigenesis and can serve as a candidate target for tumor therapy of NSCLC patients with mixed-lineage tumor features.In summary, our work provides novel insights into the tumor heterogeneity of NSCLC in terms of the identification of prevalent mixed-lineage subpopulations of cancer cells with combined signatures of SCC, ADC, and NET and offers clues for potential treatment strategies in these patients.
Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study
Authors: Manish Sadarangani, Phyumar Soe, Hennady P Shulha, Louis Valiquette, Otto G Vanderkooi, James D Kellner, Matthew P Muller, Karina A Top, Jennifer E Isenor, Allison McGeer, Mike Irvine, Gaston De Serres, Kimberly Marty, Julie A Bettinger
Journal: The Lancet Infectious Diseases (2022)
Interactive exploration of a global clinical network from a large breast cancer cohort
Authors: Nadir Sella, Anne-Sophie Hamy, Vincent Cabeli, Lauren Darrigues, Marick Laé, Fabien Reyal, Hervé Isambert
Journal: npj Digital Medicine (2022)

Despite unprecedented amount of information now available in medical records, health data remain underexploited due to their heterogeneity and complexity. Simple charts and hypothesis-driven statistics can no longer apprehend the content of information-rich clinical data. There is, therefore, a clear need for powerful interactive visualization tools enabling medical practitioners to perceive the patterns and insights gained by state-of-the-art machine learning algorithms. Here, we report an interactive graphical interface for use as the front end of a machine learning causal inference server (MIIC), to facilitate the visualization and comprehension by clinicians of relationships between clinically relevant variables. The widespread use of such tools, facilitating the interactive exploration of datasets, is crucial both for data visualization and for the generation of research hypotheses. We demonstrate the utility of the MIIC interactive interface, by exploring the clinical network of a large cohort of breast cancer patients treated with neoadjuvant chemotherapy (NAC). This example highlights, in particular, the direct and indirect links between post-NAC clinical responses and patient survival. The MIIC interactive graphical interface has the potential to help clinicians identify actionable nodes and edges in clinical networks, thereby ultimately improving the patient care pathway.
Screening policies for cytomegalovirus in pregnancy in the era of antivirals
Authors: Sophie Louise Roberts, Giles S Kendall, Sarah Edwards, Pranav Pandya, Donald Peebles, Eleni Nastouli, Haley Alchin, George Attilakos, Alasdair Bamford, Anna David, Leigh Dyet, Sarah Eisen, Sara Hillman, Angela Huertas, Alia Hussain, Seilesh Kadambari, Jonathan Kefas, Giles S Kendall, Christina Kortsalioudaki, Camille Mallet, Georgina Murray, Rafaelle Napolitano, Eleni Nastouli, Pranav Pandya, Donald Peebles, Chrysa Spyridakou, Latha Srinivasan, Daniel Stott, Fred Ushakov, Melissa Whitten
Journal: The Lancet (2022)
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study
Authors: Kevin H M Kuo, D Mark Layton, Ashutosh Lal, Hanny Al-Samkari, Joy Bhatia, Penelope A Kosinski, Bo Tong, Megan Lynch, Katrin Uhlig, Elliott P Vichinsky
Journal: The Lancet (2022)
Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models
Authors: Ming Qi, Shuran Fan, Maohua Huang, Jinghua Pan, Yong Li, Qun Miao, Wenyu Lyu, Xiaobo Li, Lijuan Deng, Shenghui Qiu, Tongzheng Liu, Weiqing Deng, Xiaodong Chu, Chang Jiang, Wenzhuo He, Liangping Xia, Yunlong Yang, Jian Hong, Qi Qi, Wenqian Yin, Xiangning Liu, Changzheng Shi, Minfeng Chen, Wencai Ye, Dongmei Zhang
Journal: Journal of Clinical Investigation (2022)

Vessel co-option has been demonstrated to mediate colorectal cancer liver metastasis (CRCLM) resistance to antiangiogenic therapy. The current mechanisms underlying vessel co-option have mainly focused on "hijacker" tumor cells, whereas the function of the "hijackee" sinusoidal blood vessels has not been explored. Here, we found that the occurrence of vessel co-option in bevacizumab-resistant CRCLM xenografts was associated with increased expression of fibroblast activation protein α (FAPα) in the co-opted hepatic stellate cells (HSCs), which was dramatically attenuated in HSC-specific conditional Fap-knockout mice bearing CRCLM allografts. Mechanistically, bevacizumab treatment induced hypoxia to upregulate the expression of fibroblast growth factor-binding protein 1 (FGFBP1) in tumor cells. Gain- or loss-of-function experiments revealed that the bevacizumab-resistant tumor cell-derived FGFBP1 induced FAPα expression by enhancing the paracrine FGF2/FGFR1/ERK1/-2/EGR1 signaling pathway in HSCs. FAPα promoted CXCL5 secretion in HSCs, which activated CXCR2 to promote the epithelial-mesenchymal transition of tumor cells and the recruitment of myeloid-derived suppressor cells. These findings were further validated in tumor tissues derived from patients with CRCLM. Targeting FAPα+ HSCs effectively disrupted the co-opted sinusoidal blood vessels and overcame bevacizumab resistance. Our study highlights the role of FAPα+ HSCs in vessel co-option and provides an effective strategy to overcome the vessel co-option-mediated bevacizumab resistance.
Cystic fibrosis transmembrane conductance regulator (CFTR): a missing link between smoking and chronic airway diseases?
Authors: Pierre-Régis Burgel, Nicolas Roche
Journal: European Respiratory Journal (2022)

Mucus abnormalities play important roles in the development and/or evolution of most, if not all, airway diseases. The airway mucus is both a crucial component of the airway's mechanical defence mechanisms against irritants and microorganisms, and a marker of airway injury: its composition is influenced by various pathophysiological mechanisms involved in acute and chronic airway diseases, including inflammation, infection, oxidative stress and protease–antiprotease imbalance. These mechanisms can induce abnormalities in mucus composition through impairments in mucin production and/or ion transport pathways that contribute to mucus hydration [1], and/or through the integration in the mucus of other components, such as extracellular DNA and other constituents of neutrophil extracellular traps. The contribution of CFTR to the pathobiology of cigarette smoke-related chronic airway diseases deserves further investigation <https://bit.ly/3FvP5Ym>
Metatranscriptomics of Nasopharyngeal Microbiota and Host Distinguish between Pneumonia and Health
Authors: Priyanka Nannapaneni, John Sundh, Stefanie Prast-Nielsen, Samuel Rhedin, Åke Örtqvist, Pontus Naucler, Birgitta Henriques-Normark
Journal: American Journal of Respiratory and Critical Care Medicine (2022)
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease
Authors: M. Naomi Horiba, Sandra J. Casak, Pallavi S. Mishra-Kalyani, Pourab Roy, Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Steven J. Lemery, Lola A. Fashoyin-Aje
Journal: Clinical Cancer Research (2022)

Abstract The FDA approved nivolumab on May 20, 2021, for the adjuvant treatment of completely resected (negative margins) esophageal or gastroesophageal junction cancer (EC/GEJC) in patients who had residual pathologic disease following chemoradiotherapy. The approval was based on data from the double-blind CheckMate 577 trial, which randomly allocated patients to receive nivolumab or placebo. Disease-free survival (DFS) was the primary endpoint. At the time of the final DFS analysis and the prespecified interim overall survival (OS) analysis, the estimated median DFS was 22.4 months [95% confidence interval (CI), 16.6–34.0] in the nivolumab arm versus 11.0 months (95% CI, 8.3–14.3) in the placebo arm, with an HR of 0.69 (95% CI, 0.56–0.85; two-sided P value = 0.0003). An unblinded review of OS did not indicate a detrimental effect on survival. Adverse reactions occurring in ≥20% of patients receiving nivolumab were fatigue/asthenia, diarrhea, nausea, rash, musculoskeletal pain, and cough. Approval of nivolumab is likely to change the treatment paradigm for the adjuvant treatment of patients with completely resected (negative margins) EC/GEJC who have residual pathologic disease following chemoradiotherapy based on the study results and favorable risk:benefit of nivolumab administration.
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Authors: Barton F. Haynes, Kevin Wiehe, Persephone Borrow, Kevin O. Saunders, Bette Korber, Kshitij Wagh, Andrew J. McMichael, Garnett Kelsoe, Beatrice H. Hahn, Frederick Alt, George M. Shaw
Journal: Nature reviews. Immunology (2022)
Plasma exchange in the intensive care unit: a narrative review
Authors: Philippe R. Bauer, Marlies Ostermann, Lene Russell, Chiara Robba, Sascha David, Bruno L. Ferreyro, Joan Cid, Pedro Castro, Nicole P. Juffermans, Luca Montini, Tasneem Pirani, Andry Van De Louw, Nathan Nielsen, Julia Wendon, Anne C. Brignier, Miet Schetz, Jan T. Kielstein, Jeffrey L. Winters, Elie Azoulay, Nina Buchtele, Thomas Staudinger, Gottfried Heinz, Gürkan Sengölge, Christian Zauner, Peter Jaksch, Karin Amrein, Peter Schellongowski, Thomas Staudinger, Anne-Pascale Meert, Dominique Benoit, Fabio Silvio Taccone, Ana Paula Pierre de Moraes, William Viana, Guilliana Moralez, Thiago Lishoa, Marcio Soares, Jorge Salluh, U. V. Silva, Sumech Shah, Sangeeta Mehta, Laveena Munshi, Balik Martin, Karvunidis Thomas, Katerina Rusinova, Jonas Nelsen, Ann M. Moeller, Anders Perner, Sylvest Meyhoff, Ramin Brandt Bukan, Lene B. Nielsen, Docent Anne Kuitunen, Miia Valkonen, Antoine Rabbat, Isabelle Vinatier, Kada Klouche, Laura Platon, Martine Nyunga, Alexandre Demoule, Julien Mayaux, Akli Chermak, Caroline Lemaitre, Elise Artaud-Macari, Elie Azoulay, Virginie Lemiale, Virginie Souppart, Michael Darmon, Lara Zafrani, Sandrine Valade, Djamel Mokart, Benjamin Gaborit, Emmanuel Canet, Amélie Séguin, Sylvie Chevret, Nicolas Terzi, Carole Schwebel, Achille Kouatchet, Fabrice Bruneel, Frédéric Pène, Anne Sophie Moreau, Christophe Girault, Francois Barbier, Aisling Mc Mahon, Brian Marsh, Ignacio Martin Loeches, Gilda Cinnella, Antonella Cotoia, Massimo Antonelli, Luca Montini, Thomas Kaufmann, Dennis Bergmans, Angélique Spoelstra-de Man, Peter Pickkers, Pleun Hemelaar, Precious Pearl Landburg, Pål Klepstad, Andreas Barratt-Due, Belen Encina, Val Hebron, Gabriel Moreno, Emilio Rodriguez Luis, Llorenç Socias Crespi, Jordi Rello, Victoria Metaxa, Yadav Hemang, Philippe R. Bauer, Andry van de Louw, Gaston Burghi
Journal: Intensive Care Medicine (2022)
Taking the Road Less Traveled: Following Molecular Trail Markers
Authors: Ana C. Veneziani, Amit M. Oza
Journal: Clinical Cancer Research (2022)

Targeted therapy largely remains an unmet therapeutic need for low-grade serous ovarian carcinomas. However, recent advances in molecular characterization are beginning to change the landscape. A recent article highlights the association of genetic alterations with clinical outcomes, widening the scope of novel targeted therapies. See related article by Manning-Geist et al., p. 4456.
American Academy of Medicine.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New and Nonofficial Remedies
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New and Non-Official Remedies
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal